The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis
- Type de publi. : Article dans une revue
- Date de publi. : 10/05/2024
-
Auteurs :
Michael CooremanJaved ButlerRobert GiuglianoFaiez ZannadLucile DzenPhilippe Huot-MarchandMartine BaudinDaniel BeardJean-Louis JunienPierre BroquaManal AbdelmalekSven Francque
-
Organismes :
Research and Development, Inventiva, New York
Inventiva [Daix]
Baylor Scott & White Research Institute
Harvard Medical School [Boston]
Brigham and Women's Hospital [Boston]
Défaillance Cardiovasculaire Aiguë et Chronique
Centre d'investigation clinique plurithématique Pierre Drouin [Nancy]
Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy]
French-Clinical Research Infrastructure Network - F-CRIN [Paris]
Research and Development, Inventiva, New York
Inventiva [Daix]
Research and Development, Inventiva, New York
Inventiva [Daix]
Research and Development, Inventiva, New York
Inventiva [Daix]
Translational Medicine Academy
Research and Development, Inventiva, New York
Inventiva [Daix]
Research and Development, Inventiva, New York
Inventiva [Daix]
Mayo Clinic [Rochester]
Antwerp University Hospital [Edegem]
Universiteit Antwerpen = University of Antwerp
- Publié dans Nature Communications le 23/10/2020
Résumé : Abstract Lanifibranor, a pan-PPAR agonist, improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH), who have poor cardiometabolic health (CMH) and cardiovascular events as major mortality cause. NATIVE trial secondary and exploratory outcomes (ClinicalTrials.gov NCT03008070) were analyzed for the effect of lanifibranor on IR, lipid and glucose metabolism, systemic inflammation, blood pressure (BP), hepatic steatosis (imaging and histological grading) for all patients of the original analysis. With lanifibranor, triglycerides, HDL-C, apolipoproteins, insulin, HOMA-IR, HbA1c, fasting glucose (FG), hs-CRP, ferritin, diastolic BP and steatosis improved significantly, independent of diabetes status: most patients with prediabetes returned to normal FG levels. Significant adiponectin increases correlated with hepatic and CMH marker improvement; patients had an average weight gain of 2.5 kg, with 49% gaining ≥2.5% weight. Therapeutic benefits were similar regardless of weight change. Here, we show that effects of lanifibranor on liver histology in MASH are accompanied with CMH improvement, indicative of potential cardiovascular clinical benefits.
Fichiers liés :
s41467-024-47919-9.pdf
Source